Casey Woodring
Stock Analyst at JP Morgan
(0.82)
# 4,034
Out of 5,182 analysts
58
Total ratings
22.22%
Success rate
-11.31%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $105 → $96 | $89.79 | +6.92% | 1 | Mar 31, 2026 | |
| TEM Tempus AI | Maintains: Neutral | $80 → $60 | $42.94 | +39.73% | 2 | Feb 25, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $78.60 | +65.39% | 3 | Feb 20, 2026 | |
| IQV IQVIA Holdings | Maintains: Overweight | $255 → $225 | $167.34 | +34.46% | 2 | Feb 6, 2026 | |
| ILMN Illumina | Maintains: Neutral | $130 → $120 | $120.93 | -0.77% | 3 | Feb 6, 2026 | |
| QGEN Qiagen | Maintains: Overweight | $55 → $60 | $40.89 | +46.74% | 5 | Feb 6, 2026 | |
| NTRA Natera | Maintains: Overweight | $250 → $260 | $193.03 | +34.69% | 3 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $165 → $190 | $175.65 | +8.17% | 10 | Dec 15, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $55 | $37.59 | +46.32% | 1 | Dec 15, 2025 | |
| BLLN BillionToOne | Maintains: Overweight | $150 → $145 | $81.13 | +78.73% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $180 | $115.06 | +56.44% | 2 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $22 | $13.85 | +58.84% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $23.27 | -35.54% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $15.36 | +4.17% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $7.90 | +51.90% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $325 | $320.00 | +1.56% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $496.11 | +31.02% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,325.01 | -3.02% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $106.81 | +40.44% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $2.97 | +102.36% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $26.51 | -13.24% | 2 | Oct 31, 2023 |
Revvity
Mar 31, 2026
Maintains: Neutral
Price Target: $105 → $96
Current: $89.79
Upside: +6.92%
Tempus AI
Feb 25, 2026
Maintains: Neutral
Price Target: $80 → $60
Current: $42.94
Upside: +39.73%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $78.60
Upside: +65.39%
IQVIA Holdings
Feb 6, 2026
Maintains: Overweight
Price Target: $255 → $225
Current: $167.34
Upside: +34.46%
Illumina
Feb 6, 2026
Maintains: Neutral
Price Target: $130 → $120
Current: $120.93
Upside: -0.77%
Qiagen
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $60
Current: $40.89
Upside: +46.74%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $193.03
Upside: +34.69%
Charles River Laboratories International
Dec 15, 2025
Maintains: Neutral
Price Target: $165 → $190
Current: $175.65
Upside: +8.17%
Bruker
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $37.59
Upside: +46.32%
BillionToOne
Dec 10, 2025
Maintains: Overweight
Price Target: $150 → $145
Current: $81.13
Upside: +78.73%
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $115.06
Upside: +56.44%
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $13.85
Upside: +58.84%
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $23.27
Upside: -35.54%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $15.36
Upside: +4.17%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $7.90
Upside: +51.90%
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $320.00
Upside: +1.56%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $496.11
Upside: +31.02%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,325.01
Upside: -3.02%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $106.81
Upside: +40.44%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $2.97
Upside: +102.36%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $26.51
Upside: -13.24%